EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model

Lenore Monterroza, Maria M Parrilla, Sarah G Samaranayake iD, Dormarie E Rivera-Rodriguez, Sung Bo Yoon, Ramireddy Bommireddy iD, Justin Hosten, Luisa Cervantes Barragan, Adam Marcus, Brian S Dobosh, Periasamy Selvaraj iD, Rabindra Tirouvanziam iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25105392 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Lenore Monterroza und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Triple Negative Breast Neoplasms, Lung Neoplasms, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is an aggressive and highly metastatic type of tumor. TNBC is often enriched in tumor-infiltrating neutrophils (TINs), which support cancer growth in part by counteracting tumor-infiltrating lymphocytes (TILs). Prior studies identified the enhancer of zeste homolog 2 (EZH2) as a pro-tumor methyltransferase in primary and metastatic TNBCs. We hypothesized that EZH2 inhibition in TNBC cells per se would exert antitumor activity by altering the tumor immune microenvironment. To test this hypothesis, we used CRISPR to generate EZH2 gene knockout (KO) and overexpressing (OE) lines from parent (wild-type—WT) 4T1 cells, an established murine TNBC model, resulting in EZH2 protein KO and OE, respectively. In vitro, EZH2 KO and OE cells showed early, transient changes in replicative capacity and invasiveness, and marked changes in surface marker profile and cytokine/chemokine secretion compared to WT cells. In vivo, EZH2 KO cells showed significantly reduced primary tumor growth and a 10-fold decrease in lung metastasis compared to WT cells, while EZH2 OE cells were unchanged. Compared to WT tumors, TIN:TIL ratios were greatly reduced in EZH2 KO tumors but unchanged in EZH2 OE tumors. Thus, EZH2 is key to 4T1 aggressiveness as its tumor-intrinsic knockout alters their in vitro secretome and in vivo primary tumor growth, TIN/TIL poise, and metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinTriple Negative Breast NeoplasmsLung NeoplasmsLymphocytes, Tumor-InfiltratingAnimalsMiceFemaleCell Line, TumorTumor MicroenvironmentCell ProliferationHumansMice, Inbred BALB CGene Knockout TechniquesDisease Models, AnimalGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

CD4+ T cellCD8+ T cellinvasionmyeloid-derived suppressor celltriple-negative breast cancertumor-infiltrating neutrophils

Substanzen

Enhancer of Zeste Homolog 2 ProteinEzh2 protein, mouseEZH2 protein, human

Autor:innen und Institutionen

  • Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • MD Program, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Microbiology & Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.

ORCID-Profile: Sarah G Samaranayake, Ramireddy Bommireddy, Periasamy Selvaraj, Rabindra Tirouvanziam

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • NIH/NIAID
  • NIH/NCI Diversity Supplement Award
  • Selvaraj and Tirouvanziam labs

Zitieren

APA

Monterroza, L., Parrilla, M. M., Samaranayake, S. G., Rivera-Rodriguez, D. E., Yoon, S. B., Bommireddy, R., Hosten, J., Barragan, L. C., Marcus, A., Dobosh, B. S., Selvaraj, P., & Tirouvanziam, R. (2024). Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105392

Vancouver

Monterroza L, Parrilla MM, Samaranayake SG, Rivera-Rodriguez DE, Yoon SB, Bommireddy R, et al. Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105392

BibTeX
@article{Monterroza2024,
  author = {Monterroza, Lenore and Parrilla, Maria M and Samaranayake, Sarah G and Rivera-Rodriguez, Dormarie E and Yoon, Sung Bo and Bommireddy, Ramireddy and Hosten, Justin and Barragan, Luisa Cervantes and Marcus, Adam and Dobosh, Brian S and Selvaraj, Periasamy and Tirouvanziam, Rabindra},
  title = {Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25105392}
}
Kostenlos starten →